Opinion|Videos|September 4, 2024
Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please highlight the study design, efficacy, and safety data of the phase 3 DIPPER trial.
- What are your thoughts on the data and how might this impact the current treatment landscape?
Advertisement
Related to this article
Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
SurVaxM Cancer Vaccine Shows Clinically Meaningful OS Signal in Newly Diagnosed Glioblastoma
3
VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer
4
FDA Accepts BLA Resubmission for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
5